

Product Data Sheet

Product Name: ST1072
Cat. No.: GC79707

Chemical Properties

Cas. No. 1402703-50-7


Formula $C_{28}H_{41}NO_4$ M.Wt 455.63

Solubility Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure



Background

ST1072 is an inhibitor of CerS4 and CerS6. ST1072 preferentially inhibits CerS6 over CerS4, and reduces the production of C 16 ceramide. ST1072 impairs TCR-mediated N-RAS activation, ERK signaling pathway, and the colocalization of CD3 / PKCθ. ST1072 decreases the production of IFN-γ as well as the migration of donor cells to target organs. ST1072 regulates immune cell populations and the expression of co-stimulatory molecules. ST1072 can be used in research related to colon cancer, cervical cancer, graft-versus-host disease, and hematologic malignancies [1] [2] [3].

In Vivo, ST1072 (2 mg/kg; i.p.; daily; day -1 to day 28 post-transplant) significantly reduces chronic

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

GVHD severity in an MHC-mismatched murine allogeneic bone marrow transplantation model, matching the efficacy of CerS6 knockout donor grafts^[3]. ST1072 (1 mg/kg; i.p.; daily; day -1 to day 14 post-transplant) significantly reduces acute GVHD severity and improves survival while preserving the GVL effect against mixed-lineage leukemia in an MHC-mismatched murine allogeneic bone marrow transplantation model^[3]. ST1072 (1 mg/kg; i.p.; daily; day -1 to day 14 post-transplant) significantly reduces donor T-cell expansion and migration to GVHD target organs in an MHC-mismatched murine allogeneic bone marrow transplantation model^[3].

In Vitro, ST1072 (10 min preincubation, 30 min reaction) potently inhibits ceramide synthase activity in HCT-116 cell microsomes, with the highest potency against C18:0-dhCer synthesis ($IC_{50} = 26.9 \mu M$) followed by C16:0-dhCer ($IC_{50} = 50.4 \mu M$) and weaker activity against C24:0-dhCer ($IC_{50} = 81.3 \mu M$)^[1]. ST1072 (0-80 μM ; 48 h) reduces the viability of HCT-116 human colon cancer cells in a concentration-dependent manner starting at 20 μM after 48 h of incubation^[1]. ST1072 (25 μM) significantly reduces C16:0-dhCer, C24:0-dhCer, and C24:1-dhCer levels in HeLa human cervical cancer cells after 48 h of incubation^[1]. ST1072 (5-30 μM ; 48 h) potently reduces ceramide levels in HeLa human cervical cancer cells, with the highest potency against C16:0-Cer ($IC_{50} = 6.8 \mu M$) followed by C14:0-Cer ($IC_{50} = 12.2 \mu M$) and C24:1-Cer ($IC_{50} = 14.5 \mu M$) after 48 h of incubation^[1]. ST1072 (50 μM ; 5 days) potently inhibits allogeneic proliferation and IFN- γ production in primary murine WT T cells^[2]. ST1072 (50 $\mu g/mL$; 24 h-5 days) inhibits TCR-mediated N-RAS activation and downstream ERK signaling in primary mouse wild-type T cells, reducing IFN- γ production in CD4 T cells, an effect reversed by active N-RAS overexpression^[3].

References:

- [1]. Schiffmann S, et al. Inhibitors of specific ceramide synthases. *Biochimie*. 2012 Feb;94(2):558-65.
- [2]. Sofi MH, et al. Ceramide synthesis regulates T cell activity and GVHD development. *JCI insight*. 2017 May 18;2(10):e91701.
- [3]. Sofi MH, et al. Ceramide synthase 6 impacts T-cell allogeneic response and graft-versus-host disease through regulating N-RAS/ERK pathway. *Leukemia*. 2022 Jul;36(7):1907-1915.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA